Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 10, October, p. 1285–1292

doi: 10.17219/acem/104543

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Targeted blockade of interleukin 9 inhibits tumor growth in murine model of pancreatic cancer

Dongcheng Lu1,B,F, Qinyi Qin1,B,C, Ronge Lei1,C,E,F, Bangli Hu1,D,E, Shanyu Qin1,A,D,F

1 First Affiliated Hospital of Guangxi Medical University, Nanning, China


Background. Interleukin 9 (IL-9) has been implicated in the pathogenesis of several tumor types, but the role of anti-IL-9 in pancreatic cancer remains unclear.
Objectives. We aimed to explore the mechanism and effects of blockading IL-9 in a pancreatic cancer mouse model.
Material and Methods. Panc02 cells were injected subcutaneously into mice to establish a mouse model. The mice were randomly categorized into 3 groups – the control group, the immunoglobulin G (IgG) group and the anti-IL-9 group – corresponding to intravenous tail injection of phosphate-buffered saline (PBS), IgG isotype antibody and anti-IL-9 antibody, respectively. Then, the expression of IL-9, interleukin-9 receptor (IL-9r), Janus kinase 1 (Jak1), Jak3, and signal transducer and activator of transcription 3 (Stat3) mRNA was tested with quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Interleukin 9 in the tumor tissue was detected using enzyme-linked immunosorbent assay (ELISA). Western blotting and immunocytochemistry were performed to detect STAT3 and phosphorylation signal transducers and activators of transcription-3 (pSTAT3). Matrix metalloproteinase 2 (MMP2), MMP9 and vascular endothelial growth factor (VEGF) levels were assessed using immunocytochemistry.
Results. Tumor weight in the anti-IL-9 group was significantly lower than in the other groups (p < 0.05). There was a remarkable survival benefit in the anti-IL-9 group compared to the other groups (p < 0.05). The concentration of IL-9 in tumor tissue was significantly downregulated in the anti-IL-9-treated mice (p < 0.05). The expression of Jak1 and Jak3 mRNA and pSTAT3, MMP2 and MMP9 proteins in the anti-IL-9 group was lower than that of the PBS or IgG groups (p < 0.05), but the STAT3 and VEGF protein levels showed no significant difference (p < 0.05).
Conclusion. Anti-IL-9 antibody could effectively restrain the growth of pancreatic cancer in mice, and this effect may partly occur by blocking the STAT3 pathway.

Key words

pancreatic cancer, JAK2/STAT3 pathway, IL-9 antibody

References (31)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
  2. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617.
  3. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci. 2012;1247:56–68.
  4. Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends Immunol. 2014;35(2):61–68.
  5. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 2010;10(10):683–687.
  6. Rivera Vargas T, Humblin E, Vegran F, Ghiringhelli F, Apetoh L. TH9 cells in anti-tumor immunity. Semin Immunopathol. 2017;39(1):39–46.
  7. Chen J, Petrus M, Bryant BR, et al. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood. 2010;116(26):5948–5956.
  8. Lv X, Feng L, Ge X, Lu K, Wang X. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2016;35(1):106.
  9. Hu B, Qiu-Lan H, Lei RE, Shi C, Jiang HX, Qin SY. Interleukin-9 promotes pancreatic cancer cells proliferation and migration via the miR-200a/beta-catenin axis. Biomed Res Int. 2017;2017:2831056.
  10. Huang Q, Lei R, Qin Q, Qin S, Jiang H, Hu B. Interleukin-9 promotes pancreatic cancer cell proliferation and migration via activation of STAT3 pathway [in Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:1228–1233.
  11. Back TA, Chouin N, Lindegren S, et al. Cure of human ovarian carcinoma solid xenografts by fractionated [211At] alpha-radioimmunotherapy: Influence of tumor absorbed dose and effect on long-term survival. J Nucl Med. 2017;58(4):598–604.
  12. Kashiwagi H, McDunn JE, Goedegebuure PS, et al. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol. 2007;14(5):1763–1771.
  13. Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 2000;128(2):273–280.
  14. Li HJ, Sun QM, Liu LZ, et al. High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome. Oncol Rep. 2015;34(2):795–802.
  15. Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 2016;138(11):2570–2578.
  16. Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16(9):553–565.
  17. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer: Science driving clinical progress. Nat Rev Cancer. 2005;5(6):459–467.
  18. Hoelzinger DB, Dominguez AL, Cohen PA, Gendler SJ. Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges. ­Cancer Res. 2014;74(23):6845–6855.
  19. Parrot T, Allard M, Oger R, et al. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells. Eur J Immunol. 2016;46(7):1770–1782.
  20. Ye ZJ, Zhou Q, Yin W, et al. Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med. 2012;186(11):1168–1179.
  21. Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother. 2011;60(12):1775–1787.
  22. Partecke LI, Sendler M, Kaeding A, et al. A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. Eur Surg Res. 2011;47(2):98–107.
  23. Mace TA, Shakya R, Pitarresi JR, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67(2):320–332.
  24. Arpin CC, Mac S, Jiang Y, et al. Applying small molecule signal transducer and activator of transcription-3 (STAT3) protein inhibitors as pancreatic cancer therapeutics. Mol Cancer Ther. 2016;15(5):794–805.
  25. Zimmers TA, Fishel ML, Bonetto A. STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol. 2016;54:28–41.
  26. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signaling in cancer: New and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746.
  27. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71(14):5020–5029.
  28. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011;186(6):3283–3288.
  29. Hornakova T, Staerk J, Royer Y, et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem. 2009;284(11):6773–6781.
  30. Liu X, Lv Z, Zou J, et al. Elevated AEG-1 expression in macrophages promotes hypopharyngeal cancer invasion through the STAT3-MMP-9 signaling pathway. Oncotarget. 2016;7(47):77244–77256.
  31. Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: An angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89(1):129–139.